These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26721599)

  • 1. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.
    Cain LE; Saag MS; Petersen M; May MT; Ingle SM; Logan R; Robins JM; Abgrall S; Shepherd BE; Deeks SG; John Gill M; Touloumi G; Vourli G; Dabis F; Vandenhende MA; Reiss P; van Sighem A; Samji H; Hogg RS; Rybniker J; Sabin CA; Jose S; Del Amo J; Moreno S; Rodríguez B; Cozzi-Lepri A; Boswell SL; Stephan C; Pérez-Hoyos S; Jarrin I; Guest JL; D'Arminio Monforte A; Antinori A; Moore R; Campbell CN; Casabona J; Meyer L; Seng R; Phillips AN; Bucher HC; Egger M; Mugavero MJ; Haubrich R; Geng EH; Olson A; Eron JJ; Napravnik S; Kitahata MM; Van Rompaey SE; Teira R; Justice AC; Tate JP; Costagliola D; Sterne JA; Hernán MA;
    Int J Epidemiol; 2016 Dec; 45(6):2038-2049. PubMed ID: 26721599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study.
    Caniglia EC; Cain LE; Sabin CA; Robins JM; Logan R; Abgrall S; Mugavero MJ; Hernández-Díaz S; Meyer L; Seng R; Drozd DR; Seage GR; Bonnet F; Dabis F; Moore RD; Reiss P; van Sighem A; Mathews WC; Del Amo J; Moreno S; Deeks SG; Muga R; Boswell SL; Ferrer E; Eron JJ; Napravnik S; Jose S; Phillips A; Justice AC; Tate JP; Gill J; Pacheco A; Veloso VG; Bucher HC; Egger M; Furrer H; Porter K; Touloumi G; Crane H; Miro JM; Sterne JA; Costagliola D; Saag M; Hernán MA; ;
    Lancet HIV; 2017 Jun; 4(6):e251-e259. PubMed ID: 28411091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals.
    Caniglia EC; Robins JM; Cain LE; Sabin C; Logan R; Abgrall S; Mugavero MJ; Hernández-Díaz S; Meyer L; Seng R; Drozd DR; Seage Iii GR; Bonnet F; Le Marec F; Moore RD; Reiss P; van Sighem A; Mathews WC; Jarrín I; Alejos B; Deeks SG; Muga R; Boswell SL; Ferrer E; Eron JJ; Gill J; Pacheco A; Grinsztejn B; Napravnik S; Jose S; Phillips A; Justice A; Tate J; Bucher HC; Egger M; Furrer H; Miro JM; Casabona J; Porter K; Touloumi G; Crane H; Costagliola D; Saag M; Hernán MA
    Stat Med; 2019 Jun; 38(13):2428-2446. PubMed ID: 30883859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study.
    Caniglia EC; Sabin C; Robins JM; Logan R; Cain LE; Abgrall S; Mugavero MJ; Hernandez-Diaz S; Meyer L; Seng R; Drozd DR; Seage GR; Bonnet F; Dabis F; Moore RR; Reiss P; van Sighem A; Mathews WC; Del Amo J; Moreno S; Deeks SG; Muga R; Boswell SL; Ferrer E; Eron JJ; Napravnik S; Jose S; Phillips A; Olson A; Justice AC; Tate JP; Bucher HC; Egger M; Touloumi G; Sterne JA; Costagliola D; Saag M; Hernán MA;
    J Acquir Immune Defic Syndr; 2016 Jun; 72(2):214-21. PubMed ID: 26895294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.
    Lodi S; Phillips A; Logan R; Olson A; Costagliola D; Abgrall S; van Sighem A; Reiss P; Miró JM; Ferrer E; Justice A; Gandhi N; Bucher HC; Furrer H; Moreno S; Monge S; Touloumi G; Pantazis N; Sterne J; Young JG; Meyer L; Seng R; Dabis F; Vandehende MA; Pérez-Hoyos S; Jarrín I; Jose S; Sabin C; Hernán MA;
    Lancet HIV; 2015 Aug; 2(8):e335-43. PubMed ID: 26423376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
    Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
    Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
    Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand.
    Jourdain G; Le Cœur S; Ngo-Giang-Huong N; Traisathit P; Cressey TR; Fregonese F; Leurent B; Collins IJ; Techapornroong M; Banchongkit S; Buranabanjasatean S; Halue G; Nilmanat A; Luekamlung N; Klinbuayaem V; Chutanunta A; Kantipong P; Bowonwatanuwong C; Lertkoonalak R; Leenasirimakul P; Tansuphasawasdikul S; Sang-A-Gad P; Pathipvanich P; Thongbuaban S; Wittayapraparat P; Eiamsirikit N; Buranawanitchakorn Y; Yutthakasemsunt N; Winiyakul N; Decker L; Barbier S; Koetsawang S; Sirirungsi W; McIntosh K; Thanprasertsuk S; Lallemant M;
    PLoS Med; 2013 Aug; 10(8):e1001494. PubMed ID: 23940461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lalama C; Schackman BR; Meyer WA; Acosta EP; Schouten J; Squires KE; Pilcher CD; Murphy RL; Koletar SL; Carlson M; Reichman RC; Bastow B; Klingman KL; Kuritzkes DR;
    JAMA; 2006 Aug; 296(7):769-81. PubMed ID: 16905783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
    ; Cain LE; Phillips A; Olson A; Sabin C; Jose S; Justice A; Tate J; Logan R; Robins JM; Sterne JA; van Sighem A; Reiss P; Young J; Fehr J; Touloumi G; Paparizos V; Esteve A; Casabona J; Monge S; Moreno S; Seng R; Meyer L; Pérez-Hoyos S; Muga R; Dabis F; Vandenhende MA; Abgrall S; Costagliola D; Hernán MA
    Clin Infect Dis; 2015 Apr; 60(8):1262-8. PubMed ID: 25567330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.
    Murray M; Hogg RS; Lima VD; May MT; Moore DM; Abgrall S; Bruyand M; D'Arminio Monforte A; Tural C; Gill MJ; Harris RJ; Reiss P; Justice A; Kirk O; Saag M; Smith CJ; Weber R; Rockstroh J; Khaykin P; Sterne JA;
    HIV Med; 2012 Feb; 13(2):89-97. PubMed ID: 21819529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States.
    Melekhin VV; Shepherd BE; Jenkins CA; Stinnette SE; Rebeiro PF; Bebawy SS; Rasbach DA; Hulgan T; Sterling TR
    AIDS Patient Care STDS; 2010 May; 24(5):279-86. PubMed ID: 20438375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals.
    Lodi S; Günthard HF; Gill J; Phillips AN; Dunn D; Vu Q; Siemieniuk R; Garcia F; Logan R; Jose S; Bucher HC; Scherrer AU; Reiss P; van Sighem A; Boender TS; Porter K; Gilson R; Paraskevis D; Simeon M; Vourli G; Moreno S; Jarrin I; Sabin C; Hernán MA
    J Acquir Immune Defic Syndr; 2019 Nov; 82(3):314-320. PubMed ID: 31609929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.